Preoperative ultrasound imaging can provide tumor size measurements. In invasive lobular carcinoma (ILC), it is unclear whether the concordance in tumor size stage (T stage) between the ultrasound and pathologic findings is dependent on the tumor T stage itself. From a cohort of 128 cases of ILC, 66 unifocal ILC cases were analyzed. The concordance between the clinical tumor size stage from ultrasound (cT) and the pathology tumor size stage (pT) varied with pT stage (P [ .0003, Fisher's exact test), with the greatest concordance rate of 95.7% (95% confidence limit, 85.2%-99.5%) observed for pT1 tumors. Caution is warranted when using ultrasonography to stage ILCs larger than pT1. Background: We systematically analyzed the extent of disease in unifocal invasive lobular carcinoma (ILC) using ultrasonography, with the histopathologic findings as the reference standard. Patients and Methods: In the present single-institution retrospective study, 128 cases of ILC were identified during a 5-year period. After exclusions, the analyzed cohort included 66 cases. Ultrasound measurements of the tumor extent along 3 axes were obtained. The tumor size was determined as the largest extent among the 3 axes and the tumor volume by ellipsoidal approximation. Pathology review provided the tumor size and volume. Correlation and regression analyses of tumor size and volume from the ultrasound and pathologic examinations were performed. The tumor stage from the ultrasound and pathologic examinations were used for the concordance analyses. Results: The median and quartiles (Q1, Q3) of tumor size from ultrasonography and pathology were 12.5 mm (Q1, 9 mm; Q3, 19 mm) and 17 mm (Q1, 12 mm; Q3, 25 mm), respectively. The corresponding data for tumor volume were 0.52 cm 3 (Q1, 0.18 cm 3 ; Q3, 1.92 cm 3 ) and 1.04 cm 3 (Q1, 0.45 cm 3 ; Q3, 2.49 cm 3 ). The ultrasound measurements correlated with the pathology-reported tumor size (Spearman r ¼ 0.678; P < .0001) and volume (Spearman r ¼ 0.699; P < .0001). The ultrasound-measured size and volume differed from the pathology-reported size and volume (P < .0001; Wilcoxon signed ranks test). Concordance between the clinical tumor size stage from ultrasound (cT) and pathology tumor size stage (pT) varied with the pT stage (P ¼ .0003, Fisher's exact test), with the greatest concordance rate of 95.7% (95% confidence limit, 85.2%-99.5%) observed for pT1 tumors. Conclusion: Ultrasonography underestimates the tumor size and volume, with the underestimation increasing for larger tumors. Hence, the concordance rate in tumor size stage between ultrasonography and pathology is tumor size dependent, with the greatest concordance rate observed for pT1 tumors.
Introduction
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer. 1 It accounts for w10% of all breast malignancies. 2 ILC poses a diagnostic challenge, because it is often poorly circumscribed and fails to form discrete masses. 3 This, perhaps, can be explained by the typical histopathologic characteristics of ILC, which include noncohesive cells that infiltrate the stroma in a single-file pattern.
Ultrasonography is widely available, inexpensive, and a valuable diagnostic tool as an adjunct to mammography. 3 Some of the most common uses of ultrasonography are to distinguish solid from cystic lesions, to evaluate palpable masses not visible by mammography, to evaluate young pregnant patients with palpable masses, and to characterize lymph nodes. [5] [6] [7] The lack of radiation and real-time nature of ultrasonography have made it the method of choice for image-guided procedures. 3, 6 Increasing evidence has shown that ultrasound examinations can detect occult cancers. 6, 8 Typically, ILC has a low mammographic sensitivity, varying from 57% to 79%, reflecting one of the most important causes of false-negative results. 8 Also, for patients with a diagnosis of ILC, the tumor size determined from the mammogram (r ¼ 0.27) has correlated poorly with the histopathologic tumor size. 9 The role of ultrasound examinations in the identification of ILC is well documented, with sensitivity ranging from 81% to 83%. 10 A meta-analysis of pooled data showed that breast magnetic resonance imaging (MRI) has a sensitivity of 93.3% for detecting lobular carcinoma, with additional lesions detected in the ipsilateral breast in 32% of patients and in the contralateral breast in 7% of patients.
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Accurate tumor measurement can guide planning for surgery and systemic therapy. 12, 13 An analysis of the Surveillance, Epidemiology,
and End ResultseMedicare database with > 20,000 patients with a diagnosis of breast carcinoma, including w2000 cases of ILCs, observed that patients with ILC are more likely to undergo an initial mastectomy (35% vs. 30%), a reoperation (28% vs. 21%), and a final mastectomy (44% vs. 36%) compared with all patients with breast cancer. 14 Analyzing the data from the Netherlands Cancer Registry, for patients with early-stage (pathologically assessed T1 and T2) cancer, patients with ILC were less likely to undergo breast-conserving surgery (43% vs. 54%) than those with ductal cancer. 15 Specific to lobular cancer, 2 large independent studies using data from the Netherlands Cancer Registry 16 and the California Cancer Registry 17 have shown that the combination of adjuvant chemotherapy and adjuvant hormonal therapy did not improve the 10-year survival rates compared with adjuvant hormonal therapy alone. Previous studies have reported on the correlation and concordance in ILC size between the imaging and histopathologic findings. 9, [18] [19] [20] [21] [22] [23] However, an analysis of the tumor volume determined using ultrasonography and its correlation and concordance with the histopathologic findings have not been adequately explored. The increasing need for 3-dimensional volume estimation to assess the response to therapy prompted the present investigation. Also, clarity is lacking in the reported data regarding whether the concordance in ILC size between the ultrasound and histopathologic findings is dependent on the tumor size itself. This is important in the context of neoadjuvant therapy. Among patients who undergo neoadjuvant chemotherapy, the pathologic complete response rate has been lower with ILC than with ductal cancer 24, 25 and is dependent on the receptor status. 25, 26 However, neoadjuvant chemotherapy, especially for clinically assessed stage T2 and T3 ILC, can be of benefit in facilitating breast-conserving surgery. 24 Accurate measurement of the tumor size combined with receptor status 25, 26 can help in identifying those subjects likely to benefit from breast conservation after neoadjuvant chemotherapy. Hence, we conducted the present systematic retrospective analysis of subjects with a diagnosis of unifocal ILC.
Patients and Methods

Human Subjects
The present study was performed in a large, urban, academic center in adherence with institutional review board approval and a protocol compliant with the Health Insurance Portability and Accountability Act. The institutional review board waived the informed consent requirement for the present retrospective study. Adult women with a pathology-verified diagnosis of ILC during a 5-year period from January 1, 2007 through December 31, 2011 were eligible for inclusion in the present study.
A search of the electronic medical records identified 127 subjects (130 breasts) with a pathology-verified diagnosis of ILC during the study period. The electronic medical records of all 127 subjects were reviewed. The following subjects were excluded: those lost to followup, including patients who had undergone surgery outside our institution (n ¼ 21), those who had undergone neoadjuvant chemotherapy between the diagnosis and surgical excision (n ¼ 5), patients with multifocal or multicentric disease (n ¼ 14), patients who had not undergone an ultrasound examination (n ¼ 6), those with negative ultrasound examination findings (n ¼ 4), and subjects with large lesions (> 65 mm in ! 1 dimension) that could not be reliably measured using ultrasonography (n ¼ 2). Patients who had undergone neoadjuvant chemotherapy between ultrasound imaging and surgical excision were excluded to avoid confounding of the tumor size and tumor volume estimates from a therapy response. Owing to the retrospective nature of the study, subjects with multifocal and multicentric disease were excluded, because the concordance in location between imaging and histopathologic findings for the multiple foci could not be ascertained. Another 9 cases were excluded because pathology reports did not include all 3 tumor dimensions of the tumor, resulting in 66 cases for the present study.
Bilateral mammography was performed in all patients. All ultrasound imaging was performed using a high-resolution ultrasound unit (IU-22; Philips Healthcare, Bothell, WA) using a 17-5 MHz or a 12-5 MHz linear array transducer. Patients with dense breast tissue and those with clinical indications underwent bilateral breast MRI in accordance with appropriate standards of care. Pathologists with expertise in breast pathology processed the surgical specimens.
Data Collection and Preparation
The following demographic and clinical characteristics were obtained: age, mammography and ultrasound results, biopsy type, and preoperative histopathologic diagnosis. 
ILC Concordance Between Ultrasound and Pathologic Findings
findings were computed, respectively, as DS ¼ S À S* and DV ¼ V À V*. From the ultrasound-measured size and the pathologyreported tumor size, the clinical tumor size stage (cT) and the pathology tumor size stage (pT), respectively, were determined in accordance with the modified version of the American Joint Committee on Cancer guidelines. The modification pertains to the use of size alone for tumor size staging (T stage) and does not consider extension to the chest wall and/or the skin.
Statistical Analysis
All continuous variables were tested to determine whether the normality assumption was satisfied. Depending on the results, parametric or nonparametric tests were used for further analysis. A correlation analysis was performed. Statistical tests were conducted to determine whether the tumor size, stage, and volume differed between the ultrasound and pathologic examinations. Simple binomial proportions were used to estimate the exact Clopper-Pearson confidence interval of the concordance rates between the pathologic findings reported and the ultrasoundderived tumor stages. Effects associated with P < .05 were considered statistically significant. All analyses were performed using statistical software (SAS, version 9.4; SAS Institute Inc, Cary, NC).
Results
The mean age AE standard deviation of the analyzed cohort of the 66 subjects was 62.4 AE 12.3 years. The diagnosis of ILC was ascertained by ultrasound-guided core needle biopsy in 64 of 66 subjects (97%), with the remainder ascertained by excisional biopsy. Of the 66 ILC cases in the cohort, most (n ¼ 54) were of the classic type. The other variants were pleomorphic (n ¼ 8), mixed pleomorphic and classic (n ¼ 2), signet ring (n ¼ 1), and histiocytoid variant (n ¼ 1). The distribution of histologic grades was grade 1 in 42, grade 2 in 11, and grade 3 in 13. The receptor status distribution was estrogen receptor positive (ER þ ), progesterone receptor positive (PR þ ), and HER2 negative (HER2
þ in 1, and triple-negative in 1. The ultrasound-measured tumor size and volume, pathology-reported tumor size and volume, and the differences in tumor size and volume between the 2 measurement methods did not satisfy the normality assumption (P < .0001; ShapiroWilks test).
Tumor Size
The median, quartiles, and range for the tumor size measured using ultrasound and pathologic examinations and their differences are summarized in Table 1 . The ultrasound-measured tumor size correlated with the pathology-reported size (Spearman r ¼ 0.678; P < .0001). For these paired measurements, the ultrasoundmeasured size differed significantly from the pathology-reported size (P < .0001, Wilcoxon signed ranks test). With the pathologydetermined tumor size from surgery as the reference standard, the median underestimation using ultrasonography was 3.5 mm. Robust regression analysis indicated that, on average, ultrasonography underestimated the tumor size by 27.2% (95% confidence limit [CL], 17%-37%).
Tumor Stage
The data were analyzed by considering the pathology-reported tumor stage (pT) that included the T1 subgroups (T1a, T1b, and T1c) and by grouping all T1 subgroups. All ILCs were stage pT1 or greater, because the minimal pathology-reported size was 6 mm ( Table 1) . Several previous studies reporting on the concordance of imaging-provided tumor size measurements with those from pathologic examination had used fixed thresholds of 5, 10, and 20 mm. 9, [18] [19] [20] [21] [22] [23] The use of fixed thresholds is suitable if the absolute difference in tumor size between the ultrasound and pathologic findings is independent of the pathology-reported tumor size. Linear regression (Figure 1 ) of the absolute difference in tumor size with pathology-reported size showed that the slope (m) was significantly different from 0 (m ¼ 0.443; P < .0001). Also, the absolute difference in tumor size varied significantly from the pathologyreported tumor stage, pT (P < .0001, Kruskal-Wallis test). Hence, concordance analyses were performed with the ultrasoundderived clinical tumor size stage (cT). The clinical tumor stage (cT) differed from the pathology reported tumor stage, pT, before and after consolidating the T1 subgroups (P < .0001, Fisher's exact test). For the cohort of 66 subjects, cT and pT were concordant in 37 subjects, resulting in overall concordance rate of 56.1% (95% CL, 43.3%-68.3%), before combining the T1 subgroups. After combining the T1 subgroups, cT and pT were concordant in 56 of 66 subjects, for an overall concordance rate of 84.9% (95% CL, 73.9%-92.5%). After combining the T1 subgroups, the concordance between cT and pT varied significantly with different pT stages (P ¼ .0003, Fisher's exact test). The pT-dependent concordance rates are summarized in Table 2 . Among the pT1 tumors, 44 of 46 tumors (95.7%) were concordant, and ultrasonography overestimated the tumor stage as cT2 in the remaining 2 ILC cases. Of the pT2 ILC cases, none were overestimated using ultrasonography, with 5 of 15 pT2 cases reported as cT1 by ultrasonography. Of the pT3 ILC cases, none were overestimated by ultrasonography, with 2 of 5 pT3 reported as cT2 and 1 of 5 pT3 reported as cT1 by ultrasonography. 
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Tumor Volume
The median, quartiles, and range for tumor volume determined from the tumor extent in 3 dimensions measured by ultrasound and pathologic examination and their difference are summarized in Table 3 . The ultrasound-measured tumor volume correlated with the pathology-reported volume (Spearman r ¼ 0.699; P < .0001).
For these paired measurements, the ultrasound-measured volume significantly differed from the pathology-reported volume (P < .0001, Wilcoxon signed ranks test). With the pathologydetermined tumor volume from surgery as the reference standard, the median underestimation using ultrasonography was 0.29 cm 3 .
Regression analysis indicated that, on average, the tumor volume measured using ultrasonography was 2.61 times smaller than that using pathologic examination. The difference in tumor volume between the ultrasound and pathologic examinations varied significantly with the pathologically determined tumor size stage, pT (P < .0001, Kruskal-Wallis test), with the difference in volume progressively increasing for larger tumors. The pT-dependent tumor volume from the ultrasound and pathologic examinations and their difference are listed in Table 3 .
Discussion
The present study retrospectively analyzed the correlation and concordance between tumor size assessed using ultrasound and histopathologic examination. The study was designed to decrease the variations that can cofound the ultrasound results by including only unifocal lesions and excluding those patients who had undergone neoadjuvant therapy. Ultrasound examination results in an underestimation of tumor size and tumor volume. However, this underestimation is dependent on the pathology-reported tumor size. In general, the underestimation increased with increasing tumor size. This implies that using a fixed threshold for concordance analyses could result in varying concordance rates according to the pathologyreported tumor size distribution in an analyzed cohort. Because the tumor size stage, more often than measured tumor size, is largely used for clinical decisions, the concordance in the tumor size stage between the ultrasound and pathology findings was analyzed.
Receptor status, 25, 26 in conjunction with the extent of disease, 24 is important when considering neoadjuvant therapy for ILCs, especially when breast conservation is considered. 24, [27] [28] [29] Breast ultrasonography is a widely available modality and can be used as a complement to further characterize lesions. Among the histologic subtypes, larger discrepancies in tumor size between the ultrasound and pathologic findings have been observed in lobular carcinomas. 30 Our observation in the present unifocal lobular carcinoma cohort was that ultrasound examination, on average, underestimated the tumor size by 27.2% and the median underestimation in tumor size was 3.5 mm. In contrast, an earlier study with 40 ILC cases reported a median difference of 7.5 mm. 30 However, the size distribution in that study 30 was different, with a median pathology-reported size of 22 mm (range, 7-140 mm) that was larger than that in the present cohort ( Table 1) . The underestimation increases with tumor size and hence is dependent on the size distribution in the study cohort. When the tumor size stage is used for concordance analysis, cT and pT were concordant in 56 of 66 subjects (84.9%), after combining the T1 subgroups. In a study of 111 cancer cases that included a small proportion of ILC cases (11 of 111; 9.9%), it was observed that ultrasonography underestimated the size for all tumors that were ! 30 mm. 31 Of the 12 cancers (both ductal and lobular) that were ! 30 mm in that study, 7 (58.3%) were underestimated to be < 30 mm. Our study differed in that it was specific to ILC cases and the underestimation increased with the tumor size. Another study reported on size measurements in 95 cancer cases, comprising mostly pT1 tumors (65 of 93; 69.9%) that included 15 cases of TLC (16.1%). The study observed that the underestimation by ultrasound examination The results from the present study, which was limited to unifocal ILC cases, are consistent with this observation. In the present study, none of the pT1 tumors were underestimated using ultrasound examination, with 96% concordant with the pathology results and 4% that were overestimated using ultrasonography. Of the pT2 ILC cases, 67% were concordant, none were overestimated using ultrasound examination, and the remaining 33% were underestimated as cT1 using ultrasonography. Among the pT3 ILC cases, 40% were concordant, none had been overestimated using ultrasonography, with underestimation for the remaining 60%, of which 40% were reported as cT2 and 20% as cT1 using ultrasonography. This suggests that ultrasound examination could be of value in staging pT1 tumors; however, caution should be exercised for pT2 and larger tumors. Although ellipsoidal approximation was used to determine the tumor volume from the pathology and ultrasound examinations, the method of measuring tumor dimensions using ultrasound and histopathologic examinations differs and, therefore, might partly account for the discrepancies observed. The dimensions measured on pathologic examination is a composite of naked eye gross evaluation of the surgical specimen, palpation of the tumor, and microscopic evaluation that can identify tumor cell infiltration into adjacent tissue or up to the surgical margin. On ultrasound imaging, the identified lesion can have inconspicuous borders, extensive acoustic shadowing, or architectural distortion as the dominant image features 32, 33 ; these can present a challenge for accurate measurement of the tumor dimensions. All these ultrasound features can be explained by the histologic growth pattern that lobular carcinomas exhibit. The single-file infiltration of atypical cells into the surrounding tissue without inducing a strong desmoplastic reaction more often results in an irregular shape and irregular or indistinct margins in ILCs. 34 The tumor volume measurements, along with the breast dimensions, are important for breast reconstruction surgical planning (fat grafting, breast implant, or flap procedures), especially when performed after lumpectomy. Ultrasound examination underestimated the measured tumor volume, with a median underestimation of 0.29 cm 3 .
When the ultrasound-measured tumor volume alone is available for surgical planning, the difference in tumor volume between the ultrasound and pathology findings listed in Table 3 can provide an approximate guideline regarding the true disease extent.
Our study had some limitations. It was a single-institution retrospective study, in which most of the tumors (46 of 66, 70%) were stage pT1. The sample size for tumors larger than pT1 was relatively small, and we observed greater discordancy rates with these tumors. Also, our study was limited to unifocal ILCs, although it is known that ILCs manifest more often as multifocal and multicentric disease than as ductal cancer. The tumor volume was estimated using the ellipsoidal approximation; however, tumors are asymmetric and could have contributed to the uncertainties in measurement. Regarding the use of MRI, it was not standard practice at our institution during the study period to perform MRI for all patients with ILC. Furthermore, when MRI was performed, it was performed after the biopsy. Because the presence of clip artifacts and postbiopsy inflammation can confound the size measurements, it would not be a reliable or accurate comparison. Of the 66 subjects, only 33 had undergone an MRI examination, of whom 4 had substantial clip artifacts and 2 had diffuse nonemass-like enhancement, precluding size measurements. Hence, we did not include the MRI-measured size, and the scope of the present study was to compare the ultrasound and pathology measurements. A larger study, ideally with ultrasound and MRI measurements performed before biopsy, could be of clinical importance.
Conclusion
An underestimation of tumor size and volume results from using ultrasonography, when the pathologic findings are considered the reference standard. However, this underestimation is dependent on the pathology-reported tumor size and volume, with the underestimation increasing for larger tumors. Hence, the concordance rate in tumor size stage between ultrasound and pathologic examination is tumor size dependent, with the greatest concordance rate observed for pT1 tumors. Caution should be exercised for the tumor size evaluation using ultrasound in large, invasive lobular carcinoma. 
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Clinical Practice Points
The tumor size and volume are underestimated using ultrasonography and the underestimation increased with tumor size. The concordance rate in tumor size stage between ultrasound and pathologic examination is tumor size dependent, with the greatest concordance rate observed for pT1 tumors. Caution should be exercised for tumor size evaluation using ultrasound in large ILC.
